A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hy...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Witzig, TE, Laumann, KM, Lacy, MQ, Hayman, SR, Dispenzieri, A, Kumar, S, Reeder, CB, Roy, V, Lust, JA, Gertz, MA, Greipp, PR, Hassoun, H, Mandrekar, SJ, Rajkumar, SV
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912579/
https://ncbi.nlm.nih.gov/pubmed/22902362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.236
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg